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 Because kidney allograft s transplanted 
into sensitized recipients with donor-reac-
tive antibodies against human leukocyte 
antigen (HLA) are rapidly rejected, 1 the 
current standard of care is to avoid trans-
plantation in such donor – recipient com-
binations. As a consequence of this 
practice, sensitized transplant candidates 
have prolonged waiting times, and sensi-
tized candidates constitute an increasingly 
large proportion of the transplant waiting 
list. Low titers of anti-HLA antibodies 
below detection thresholds and antibodies 
that develop  de novo aft er transplantation 
can also injure allograft  tissue. Acute vas-
cular rejection, chronic fi brosis, tubular 
atrophy, and ultimately graft  failure are in 
part antibody mediated. 2 Currently avail-
able immunosuppression adequately con-
trols pathogenic alloreactive T cells but is 
inadequate to prevent or treat alloanti-
body formation or antibody-initiated 
injury. Short- and long-term kidney trans-
plant outcomes are far worse when recip-
ients ’ sera contain anti-donor HLA 
antibodies. 2,3 Several strategies attempting 
to target antibodies and B cells, including 
antibody removal by plasmapheresis, 
B-cell depletion with anti-CD20 (rituxi-
mab), and blockade of antibody-mediated 
eff ector functions with intravenous immu-
noglobulin, have met with limited success 
in preventing or reversing alloantibody-
associated rejection (reviewed by Stegall 
and Gloor 4 ). 
 Data derived from animal models and 
from human transplant recipients indi-
cate that antibody-initiated complement 
activation is one dominant mechanism 
through which anti-HLA antibodies 
cause allograft  injury. Alloantibodies that 
bind to HLA molecules expressed on 
donor endothelium are cross-linked by 
the C1 complex (C1qrs), which under-
goes a conformational change to initiate 
classical pathway complement activation 
( Figure 1a ). Cleavage of C4 and subse-
quently C2 yields a C3 convertase that 
functions as a key amplifi cation step of the 
cascade. Downstream cleavage of C3 to 
C3b followed by cleavage of C5 to C5b 
releases the proinfl ammatory anaphyla-
toxins C3a and C5a, respectively, and ini-
tiates formation of the C5b-9 membrane 
attack complex ( Figure 1a ). Resultant local 
infl ammation, denudation of the vascular 
endothelium, thrombus formation, and 
intravascular coagulation can lead to vas-
culitis, tissue ischemia, and ultimately 
graft  failure. C4d, a C4 cleavage end prod-
uct, covalently binds to cell membranes, 
and tissue staining for C4d has been 
widely accepted as a diagnostic tool indic-
ative of antibody-mediated rejection. 5 Th e 
recognition that antibody-mediated rejec-
tion is, at least in part, classical pathway 
complement dependent has raised the 
possibility that complement inhibition 
could be used as a therapeutic strategy for 
this disease. 
 Tillou  et al. 6 (this issue) use a novel 
approach in an eff ort to prevent antibody-
mediated rejection by blocking comple-
ment activation with recombinant C1 
inhibitor (C1INH). C1INH is a natural, 
circulating, serum protein and a member 
of the serpin family of serine protease 
inhibitors. 7 It binds to and disengages C1r 
and C1s, inactivating the C1 complex, 
thereby preventing classical pathway com-
plement activation ( Figure 1b ). C1INH is 
not specifi c for the C1 complex. Other 
substrates include mannose-binding 
lectin-associated serine proteases (MASPs), 
which initiate the complement mannose-
binding lectin pathway, the proinfl am-
matory mediator kallikrein, and the 
coagulation pathway components factor 
XIIa and factor XIa. 7 Defi ciency or block-
ade of C1INH function is the etiology 
underlying hereditary angioedema. 7 
 Tillou and colleagues 6 developed a 
model of antibody-induced kidney rejec-
tion in baboons by preimmunizing the 
recipients with peripheral blood cells 
obtained from an unrelated donor. Fol-
lowing sensitization, the authors docu-
mented anti-donor antibodies in the 
serum and demonstrated that the anti-
bodies mediated complement-depend-
ent lysis of donor cells  in vitro . Upon 
transplantation, the research group 
found that kidneys from the donor to 
which they were sensitized were rejected 
with accelerated kinetics as compared 
with controls (2 versus 6 days), and the 
rejected kidneys exhibited evidence of 
antibody-initiated, complement-medi-
ated injury. Administration of recom-
binant C1INH prolonged survival of the 
allograft s transplanted into the sensi-
tized recipients as compared with non-
sensitized controls, but rejection ensued 
essentially immediately upon halting 
of the treatment. Serum complement 
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 Current treatment for antibody-mediated kidney transplant rejection is 
inadequate. Tillou and colleagues administered recombinant C1 
inhibitor to block complement activation to prevent antibody-initiated 
injury in sensitized baboon recipients of kidney allografts. These early 
but encouraging results support further testing of the safety and 
efficacy of complement inhibition as part of a comprehensive strategy 
to treat this disease, both in animal models and ultimately in humans. 
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activity was diminished during therapy, 
and weaker staining for complement 
activation products was noted in biop-
sies of the functioning allografts in 
C1INH-treated animals. 
 Together the data provide  ‘ proof of 
concept ’ that C1INH can limit comple-
ment-dependent, antibody-mediated 
kidney rejection in a primate model. 
Th e clinical impact of the intervention 
was modest, prolonging graft  survival 
by about 4 days, and longer-term effi  -
cacy of the treatment regimen was not 
tested. Th e reported data are consistent 
with the interpretation that the eff ects 
of C1INH in this model are at least in 
part related to inhibition of classical 
pathway complement activation. 
Whether additional mechanisms are 
in play, including blockade of the 
mannose-binding lectin pathway, inhibi-
tion of kallikrein activation, and / or the 
restraining of intravascular coagulation, 
was not determined. 
 Th e data add to the fi ndings published 
by other research groups who used alter-
native complement inhibition strategies 
in attempts to prevent or treat antibody-
mediated allograft injury. Transgenic 
overexpression of the complement regu-
latory proteins decay-accelerating factor 
(CD55) and membrane cofactor protein 
(CD46), which dissociate C3 convertases 
(limiting downstream complement 
 activation), has been used with limited 
 success to prolong survival of antibody-
mediated allograft and xenograft 
rejection in large animals. 8 An antibody 
that blocks complement activation at 
the C5 convertase step was demonstrated 
to prevent antibody-mediated heart 
graft injury in mice, 9 and anecdotal 
reports in human kidney transplant 
recipients using an analogous reagent 
show promise. 4 
 Th erapy with C1INH has a theoretical 
advantage compared with these other 
approaches in that C1INH predomi-
nantly targets classical pathway comple-
ment activation, without significant 
eff ects on alternative pathway and com-
mon pathway complement function. By 
permitting complement-dependent pro-
tection against some invading patho-
genic organisms, C1INH-induced 
complement inhibition could lessen the 
likelihood of certain opportunistic infec-
tions. Ultimately, comparative studies 
will be required to assess the relative 
effi  cacy and safety of the diff erent com-
plement inhibitors. 
 While complement activation clearly 
functions as one effector mechanism 
underlying antibody-induced allograft  
injury, alloantibodies can directly trans-
duce proliferative signals to endothelial 
cells upon binding to class I HLA, 10 a 
mechanism that probably contributes to 
the development of allograft vasculo-
pathy. Alloantibodies can also cause 
damage through Fc receptor-dependent 
processes by activating macrophages and 
natural killer cells, among other cell 
types. 2 Thus, complement inhibition 
alone is unlikely to fully prevent allo-
antibody-initiated pathology of trans-
planted organs. 
 How could one envision using comple-
ment inhibitors such as C1INH in the 
transplant clinic? One possible approach 
would be to use this agent in the setting 
of antibody-mediated rejection as a tem-
porizing treatment that prevents or halts 
acute complement-dependent tissue 
damage while additional therapies aimed 
at removing antibodies and / or eliminat-
ing antibody-secreting B cells and plasma 
cells are implemented. Without addi-
tional clinical data, the presumed risk of 
infection associated with complement 
inhibition, particularly in a setting in 
which other immunosuppressant drugs 
are being administered, is still too great 
for the extended use of complement 
inhibitors to be justifi ed in transplant 
recipients. Removal of the alloantibody 
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 Figure 1  |  Mechanism of C1 inhibitor (C1INH). Schematic diagram illustrating ( a ) classical 
pathway complement activation initiated by C1q complex cross-linking of anti-HLA antibody 
bound to donor vascular endothelium, and ( b ) the inhibitory mechanism of C1INH. HLA, human 
leukocyte antigen; MAC, membrane attack complex; MBL, mannose-binding lectin. 
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(and / or its cellular source) will likely be 
required in order (1) to prevent 
 recurrence of complement-mediated 
injury and (2) to prevent graft  pathology 
induced by complement-independent 
mechanisms initiated by the alloanti-
body. Newer agents targeting B cells and 
plasma cells, including proteosome 
inhibitors that are currently being tested 
in transplantation, 4 may prove to be 
more effi  cacious than currently available 
reagents for this purpose. 
 Th e report by Tillou  et al. 6 represents a 
small but important step toward develop-
ing an eff ective therapeutic strategy for 
antibody-mediated transplant rejection. 
Th e fi ndings support further development 
and testing of the safety and effi  cacy of 
complement inhibition as part of a 
comprehensive strategy to treat this 
disease in humans. 
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 Regulation of salt reabsorption in the 
distal nephron, that is, the tubular seg-
ments located beyond the macula densa, 
plays a key role in defi ning the fi nal con-
centration of salt in urine and thus, on a 
long-term basis, helps defi ne blood pres-
sure levels. To date, all monogenic dis-
eases featuring arterial hypertension or 
hypotension in which the diseased gene 
has been discovered are due to muta-
tions in genes that encode proteins 
known to be directly involved in salt rea-
bsorption in the distal nephron. One of 
these genes is  SLC12A3 , encoding the 
thiazide-sensitive Na   +   – Cl   −   cotrans-
porter (NCC), which is heavily expressed 
in the apical membrane of the distal 
 convoluted tubule (DCT). Th e activity of 
NCC is important for salt reabsorption 
and also for potassium secretion, because 
the salt reabsorption rate in the DCT 
defi nes sodium delivery to the collecting 
duct, which is necessary for the sodium /
 potassium exchange between the epithe-
lial sodium channel, ENaC, and the 
apical potassium channels ROMK and 
BK in order to promote potassium secre-
tion. Th e importance of NCC in blood 
pressure regulation has been clearly dem-
onstrated over the years, as inhibition of 
NCC with thiazides reduces blood pres-
sure in many hypertensive patients. 
Additionally, inactivating mutations 
of the  SLC12A3 gene are the cause of 
Gitelman ’ s disease, an inherited syndrome 
featuring arterial hypotension and 
hypokalemia. On the other hand, loss of 
proper regulation of NCC by the mutant 
with-no-lysine serine / threonine kinases 
(WNKs) WNK1 and WNK4 seems to be 
an important mechanism for the devel-
opment of the arterial hypertension and 
hyperkalemia seen in pseudohypoaldos-
teronism type II. 1 Th us, modulation of 
NCC activity is a growing fi eld of study, 
since as we learn about how this cotrans-
porter is regulated, we increase the pos-
sibilities for understanding complex 
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 Vasopressin is a modulator of salt and water reabsorption, with known 
effects in the thick ascending limb and the collecting duct. Pedersen 
 et al. present evidence that vasopressin administration increases the 
phosphorylation of the apical thiazide-sensitive Na   +   – Cl   −   
cotransporter in the distal convoluted tubule. These effects appear to 
be independent of the renin – angiotensin system and to be mediated 
by the intracellular kinase SPAK. These observations expand the 
vasopressin-sensitive region of the nephron. 
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